Related Experiment Video
Updated: Jul 8, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Enhanced H. pylori Treatment Using a β-Cyclodextrin-Propolis Complex: A Randomized Clinical Trial
Aisa Mehri1, Shabnam Pourmoslemi1, Alireza Khalilian2
1Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran, umsha.ac.ir.
Background:
Helicobacter pylori infection poses a significant global health burden, with rising antibiotic resistance and treatment-related side effects highlighting the need for adjunctive therapies. Propolis, a natural resin with known antimicrobial and anti-inflammatory properties, suffers from poor solubility and bioavailability. This study evaluated a β-cyclodextrin-propolis complex designed to enhance delivery and therapeutic efficacy in H. pylori-infected patients.
Materials And Methods:
In a double-blind, randomized clinical trial at Hamadan University of Medical Sciences, biopsy-confirmed H. pylori patients received standard quadruple therapy plus omeprazole. The treatment group (n = 28) also received 250 mg/day of the β-cyclodextrin-propolis complex for 2 months; the control group (n = 12) received placebo capsules. Outcomes were assessed using fecal antigen tests and gastrointestinal symptom questionnaires 2 months posttreatment. Characterization of the complex was performed using FESEM, FTIR, and drug release profiling in PBS (pH 7.4).
Results:
The complex demonstrated a successful formation and a sustained propolis release profile. Clinically, 57.1% of treated patients achieved negative antigen tests and symptom resolution, compared with 41.6% in the control group. Adverse effects were mild and comparable between groups.
Conclusion:
These findings suggest that the β-cyclodextrin-propolis complex may serve as an effective natural adjunct to standard H. pylori treatment, offering potential benefits in eradication rates and symptom relief.
Trial Registration:
Iranian Registry of Clinical Trials (IRCT): 20230503058065N1.
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Gastritis II: Pathophysiology
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...